Laxxon Medical Announces Development of Non-Invasive Oral GLP-1 Asset

Laxxon Medical has unveiled its development program for LXM.2, a 3D printed oral GLP-1 receptor agonist designed for the treatment of obesity in adults and pediatric patients aged 12 and older. The announcement was made today in New York.

LXM.2 is an enterically coated tablet that incorporates a permeation enhancer to increase bioavailability, leveraging Laxxon Medical's SPID® technology. Dr. Achim Schneeberger, the company's Chief Scientific Officer, highlighted the challenges faced with traditional manufacturing methods and emphasized the advantages of SPID® technology.

The FDA has already approved the active pharmaceutical ingredient in LXM.2 for use in the specified patient group. Laxxon Medical plans to use the 505(b)2 pathway for a speedy development process, with an NDA submission target set for early 2027.

Helmut Kerschbaumer, CEO of Laxxon Medical, stated that LXM.2 could provide a more convenient alternative to injectable medications, potentially improving treatment adherence and long-term health outcomes for obesity patients. Laxxon is currently seeking partnerships or licensing opportunities for LXM.2 and will attend BIO in San Diego from June 3-8, 2024.